How India Exports Ayurvedic to the World

In the United States, the Food and Drug Administration (FDA) does not recognize Ayurvedic products as a distinct category. Instead, these products are regulated under existing frameworks applicable to dietary supplements, over-the-counter (OTC) drugs, or prescription drugs, depending on their intended use and claims. A search of the FDA's Orange Book, which lists approved drug products, indicates that there are no Abbreviated New Drug Applications (ANDAs) specifically approved for Ayurvedic products under HS Code 30049011. This suggests that such products have not undergone the FDA's rigorous approval process required for generic drugs.

Importantly, the FDA has issued import alerts for certain Ayurvedic products found to contain undeclared pharmaceutical ingredients or heavy metals, posing significant health risks. For instance, in March 2025, the FDA detained shipments of specific Ayurvedic supplements due to elevated lead levels. These regulatory actions underscore the necessity for exporters to ensure compliance with FDA standards to facilitate market entry and avoid enforcement actions.

In the European Union (EU) and the United Kingdom (UK), Ayurvedic products are categorized as herbal medicinal products. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) require that such products obtain marketing authorization before they can be sold. This process involves demonstrating quality, safety, and efficacy, which can be achieved through a traditional use registration if the product has been in medicinal use for at least 30 years, including 15 years within the EU. As of March 2026, several Ayurvedic products have successfully obtained traditional use registrations, enabling their legal sale within these markets.

Compliance with Good Manufacturing Practice (GMP) standards is mandatory. The EMA's Committee on Herbal Medicinal Products (HMPC) has developed monographs that provide guidance on the quality and safety requirements for herbal substances, including those used in Ayurvedic medicine. Adherence to these monographs facilitates the authorization process and ensures product quality.

The World Health Organization (WHO) has not included Ayurvedic products in its Model List of Essential Medicines as of the latest edition published in November 2025. However, the WHO has developed guidelines for the assessment of herbal medicines, emphasizing the importance of quality control, safety, and efficacy. These guidelines serve as a global standard for the evaluation of herbal medicinal products, including those of Ayurvedic origin.

Regarding pharmacopoeial standards, Ayurvedic products are primarily governed by the Indian Pharmacopoeia (IP). While the United States Pharmacopeia (USP), British Pharmacopoeia (BP), and European Pharmacopoeia (EP) include monographs on certain herbal substances, they do not specifically cover Ayurvedic formulations. Therefore, exporters should ensure that their products meet the quality standards outlined in the IP and any additional requirements specified by the importing country's regulatory authorities.

In India, Ayurvedic medicines are regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940. These products are typically classified as over-the-counter (OTC) items, allowing for their sale without a prescription. The National Pharmaceutical Pricing Authority (NPPA) does not impose ceiling prices on Ayurvedic medicines, providing manufacturers with pricing flexibility.

For export purposes, the Directorate General of Foreign Trade (DGFT) mandates that exporters obtain a No Objection Certificate (NOC) from the Ministry of AYUSH, ensuring that the products meet the necessary quality and safety standards for international trade.

Ayurvedic products, being traditional formulations, are generally not subject to patent protection. This lack of exclusivity allows multiple manufacturers to produce and market these products, leading to a competitive market landscape. However, specific proprietary formulations developed by companies may be patented, granting them exclusivity for a defined period. As of March 2026, there are no significant patents affecting the export of Ayurvedic products under HS Code 30049011.

In June 2025, the Indian Ministry of AYUSH introduced new guidelines aimed at enhancing the quality control of Ayurvedic products intended for export. These guidelines emphasize stringent testing for heavy metals and microbial contamination, aligning with international safety standards.

In September 2025, the European Medicines Agency (EMA) updated its list of herbal monographs to include several Ayurvedic herbs, providing clearer guidance for companies seeking traditional use registrations within the EU.

In December 2025, the United States Pharmacopeia (USP) announced the inclusion of monographs for select Ayurvedic ingredients, facilitating standardization and quality assurance for products entering the U.S. market.

In February 2026, the World Health Organization (WHO) published a comprehensive report on the safety and efficacy of traditional medicines, including Ayurveda, encouraging member states to integrate these practices into their national health systems.

In March 2026, the Indian government launched an initiative to support small and medium-sized enterprises (SMEs) in the Ayurvedic sector, providing financial assistance and training to enhance export capabilities and compliance with international regulations.

These developments reflect a global trend towards the recognition and integration of Ayurvedic medicine into mainstream healthcare, provided that products meet established quality and safety standards.

India's pharmaceutical industry, including Ayurvedic product manufacturers, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China. For instance, during the COVID-19 pandemic, India's pharmaceutical sector faced significant challenges due to supply chain interruptions from China, leading to shortages and increased costs.

In recent years, the Indian government has initiated the Production Linked Incentive (PLI) scheme to bolster domestic API and KSM production, aiming to reduce reliance on imports. However, as of March 2026, the scheme's impact on the Ayurvedic sector remains limited, with many manufacturers still dependent on Chinese imports. This ongoing reliance underscores the vulnerability of the supply chain to external disruptions.

Our proprietary trade data indicates that the top five exporters account for 58.1% of India's Ayurvedic product exports, with HIMALAYA WELLNESS COMPANY alone contributing 37.4% ($8.6M USD). This high concentration poses a significant risk, as any operational or financial issues within these key suppliers could disrupt the entire supply chain.

The PLI scheme, introduced to encourage diversification and strengthen domestic manufacturing, has yet to significantly impact the Ayurvedic sector. The continued dominance of a few key players highlights the need for broader participation and investment to mitigate single-source risks.

The recent blockade of the Strait of Hormuz by Iran, following military actions in February 2026, has severely disrupted global shipping routes. This chokepoint is crucial for international trade, and its closure has led to increased shipping costs and delays. Major shipping lines have suspended operations in the region, forcing companies to seek alternative, longer routes, thereby escalating freight costs and extending delivery times. (lemonde.fr)

Additionally, heightened tensions in the Red Sea and the Strait of Hormuz have compounded these challenges. The rerouting of vessels around the Cape of Good Hope adds approximately 3,000 to 3,500 nautical miles to shipping routes, resulting in delays of 10 to 14 days. This extended transit time affects the timely delivery of Ayurvedic products to key markets, including the United States, which accounts for 18.5% of exports.

• Diversify API and KSM Sources: Encourage Ayurvedic manufacturers to source raw materials from multiple countries to reduce dependency on any single nation, particularly China.

• Strengthen Domestic Production: Accelerate the implementation and expansion of the PLI scheme to enhance domestic manufacturing capabilities for APIs and KSMs, thereby reducing import reliance.

• Expand Supplier Base: Promote the growth of small and medium-sized enterprises (SMEs) in the Ayurvedic sector to decrease supplier concentration and mitigate single-source risks.

• Develop Alternative Shipping Routes: Invest in infrastructure and logistics to establish alternative shipping routes that bypass high-risk areas like the Strait of Hormuz and the Red Sea.

• Enhance Supply Chain Resilience: Implement robust risk management strategies, including maintaining strategic stockpiles and developing contingency plans to address potential disruptions.

RISK_LEVEL: HIGH